Novel article on SER140 in diabetes made publicly available in Journal of Diabetes Research

Oslo, February 5, 2016: Serodus (Oslo Axess: SER), are pleased to inform that an article on SER140 has been published in the Journal of Diabetes Research under the title ” The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice”. The article is available on

Abstract from the article:

”The cytokine interleukin-1β (IL-1β) is known to stimulate proinflammatory immune responses and impair β-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1β receptor antagonist, on diabetes progression and cellular pancreatic changes in female nonobese diabetic (NOD) mice. Eight weeks of treatment with SER140 reduced the incidence of diabetes by more than 50% compared with vehicle, decreased blood glucose, and increased plasma insulin. Additionally, SER140 changed the endocrine and immune cells dynamics in the NOD mouse pancreas. Together, the data suggest that SER140 treatment postpones the onset of diabetes in female NOD mice by interfering with IL-1β activated pathways.”

 ”The results from the study are very interesting and encouraging for the future development of the compound. We are very pleased both with the study results and being able to share this knowledge through this publications,” says Eva Steiness, CEO of Serodus.


For more information contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199


Serodus ASA is a drug development company listed on Oslo Stock Exchange, focusing on new therapeutic products for the treatment of cardiovascular and metabolic diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.